Brief: RhoVac: Cancer Vaccine RV001 Shows Positive Results
Dec 13 (Reuters) - RHOVAC AB RHOVAC.TE :
* POSITIVE IMMUNE MONITORING RESULTS HAVE BEEN DEMONSTRATED
WITH
THE COMPANY'S CANCER VACCINE RV001
Source text for Eikon: ID:nWkr5ZCt1N
Further company coverage: RHOVAC.TE
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 587720920;))
Recent news on Chosa Oncology AB
See all newsBrief: Chosa Oncology Appoints Gerton Jönsson As New Chief Financial Officer
Brief: CHOSA Oncology AB Says Postpones Publication Of Interim Report Q4 2024
Brief: Chosa Oncology Carried Out Directed Issue Of Sek 1,55 Mln To Further Increase Business Development Activities
Brief: Chosa Oncology Announces Decision To Postpone Release Of Interim Report For Q2 2023
Brief: Chosa Oncology AB Publishes Results From Clinical Phase 2 Trial Of Liposomal Formulation In Breast Cancer, Using Predictive Marker For Cisplatin